This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction

In the present study, we analysed in detail nuclear autoantibodies and their associations
in systemic sclerosis (SSc) patients included in the German Network for Systemic Scleroderma
Registry.

Methods

Sera of 863 patients were analysed according to a standardised protocol including
immunofluorescence, immunoprecipitation, line immunoassay and immunodiffusion.

Results

Antinuclear antibodies (ANA) were detected in 94.2% of patients. In 81.6%, at least
one of the autoantibodies highly associated with SSc or with overlap syndromes with
scleroderma features was detected, that is, anti-centromere (35.9%) or anti-topoisomerase
I (30.1%), followed in markedly lower frequency by antibodies to PM-Scl (4.9%), U1-ribonucleoprotein
(U1-RNP) (4.8%), RNA polymerases (RNAPs) (3.8%), fibrillarin (1.4%), Ku (1.2%), aminoacyl-transfer
RNA synthetases (0.5%), To (0.2%) and U11-RNP (0.1%). We found that the simultaneous
presence of SSc-associated autoantibodies was rare (1.6%). Furthermore, additional
autoantibodies were detected in 55.4% of the patients with SSc, of which anti-Ro/anti-La,
anti-mitochondrial and anti-p25/p23 antibodies were most frequent. The coexistence
of SSc-associated and other autoantibodies was common (43% of patients). SSc-associated
autoantibodies disclosed characteristic associations with clinical features of patients,
some of which were previously not acknowledged.

Conclusions

This study shows that five autoantigens (that is, centromere, topoisomerase I, PM-Scl,
U1-RNP and RNAP) detected more than 95% of the known SSc-associated antibody responses
in ANA-positive SSc patients and characterise around 79% of all SSc patients in a
central European cohort. These data confirm and extend previous data underlining the
central role of the determination of ANAs in defining the diagnosis, subset allocation
and prognosis of SSc patients.

Keywords:

Introduction

Autoantibodies targeting characteristic nuclear antigens are one of the hallmarks
of systemic sclerosis (SSc) [1-3]. The occurrence of different antinuclear antibodies (ANAs) is associated with distinct
disease subtypes and with differences in disease severity, including extent of skin
involvement, internal organ manifestation and prognosis. Although the current SSc
criteria of the American College of Rheumatology [4] do not include the presence of ANAs, The detection of scleroderma-associated antibodies
may be a valuable tool in the diagnosis of patients with very early SSc or only subtle
symptoms [5,6]. For instance, in a recent study of patients with Raynaud's phenomenon, the presence
of ANAs (adjusted HR = 5.67) and SSc-associated antibodies (HR = 4.7) was the strongest
independent predictor of definite SSc [6]. Some of the autoantibodies in SSc are regarded as disease-specific and can be correlated
with genetic, demographic, diagnostic, clinical and prognostic aspects of the disease
[1,3]. Therefore, autoantibodies are pivotal tools in the diagnosis of SSc by helping clinicians
make decisions whether to perform further, more detailed and efficient diagnostic
procedures, as well as decisions addressing disease management.

For frequently occurring antibodies such as anti-centromere (ACA) and anti-topoisomerase
I (ATA), reliable detection systems based on ELISA or other binding tests have been
developed. Other antibodies (that is, to fibrillarin, RNA polymerases (RNAPs) and
so on) are not identified by common test procedures, but rather by laboratories able
to perform sophisticated procedures to confirm the results on the basis of more than
one independent method. Even for the most common autoantibodies, the choice of the
detection method used is critical to the sensitivity and specificity of the results
and hence their diagnostic value [7].

Researchers in numerous studies have examined the presence of antibodies to single
predefined antigens in SSc and their clinical associations, whereas many of the investigators
who have comprehensively examined large SSc patient cohorts have often restricted
their autoantibody analyses to the most common SSc antibodies, ACA and ATA [8-12], or analysed only a few additional antibodies [13-17]. The aim of this study was therefore to characterise all known non-organ-specific,
SSc-associated autoantibodies, as well as other, potentially new nuclear autoantibodies
by using a standardised protocol in the large SSc patient cohort included in the German
Network for Systemic Scleroderma Registry, and to correlate these findings with the
clinical characteristics of these patients.

Materials and methods

Patients

Serum samples from 863 consecutive patients included in the German Network for Systemic
Scleroderma Registry between 2004 and 2007 from 23 different clinical centres were
analysed. Patient data are gathered and registered using a consensual registration
form and reference documents with item definitions and recommendations for organ-specific
diagnostic procedures as previously described [18,19]. Of the patients included, 82.9% were female, their mean age ± SD was 58.0 ± 13.4
years (median = 60 years, range 12 to 93). The patients' age at disease onset ranged
from 3 to 87 years (median = 49 years, mean = 47.7 ± 14.2).

The registry defines five subsets, that is, limited cutaneous and diffuse cutaneous
SSc [20], overlap syndrome [21,22], systemic sclerosis sine scleroderma [23,24] and undifferentiated connective tissue disease with features of scleroderma [25,26], as recently described [18]. The latter subset corresponds largely to the subgroup 'early SSc' as described by
LeRoy and Medsger [5] but may also include patients who will never develop definite SSc. The study, including
the patients' informed consent regarding data storage, was approved by the lead Ethics
committee of the Cologne University Hospital and by the respective ethics committees
of the contributing centres.

Autoantibody analysis

To detect SSc-associated autoantibodies in a comprehensive way, we used the search
strategy commonly performed in diagnostic procedures for connective tissue diseases
based on a HEp-2 cell immunofluorescence assay followed by tests using cellular extracts
and/or recombinant antigens. This strategy is focused on circulating antibodies against
non-organ-specific cellular autoantigens. Cell- or tissue-specific autoantibodies,
which have also been described in scleroderma patients [3], were not included in the analytical protocol. At least one serum draw from each
patient (N = 863) was analysed for circulating autoantibodies by a predefined protocol (Figure
1) with at least four assay systems performed in a single laboratory by a single group
of technologists.

Indirect immunofluorescence using fluorescein isothiocyanate-conjugated goat anti-human
immunoglobulin G was performed as a screening method for the detection of ANAs on
HEp-2 cells (HEp-20-10; Euroimmun, Lübeck, Germany) seeded onto a microscope slide
[27]. Titres of at least 1:80 dilution were regarded as positive. Different nuclear and
cytoplasmic fluorescence patterns were documented.

Immunoprecipitation (IP) of radiolabelled HeLa cell extract was performed as described
[28,29] with slight modifications. In brief, HeLa S3 cells in suspension culture in methionine-deficient
RPMI medium with 10% dialyzed foetal bovine serum were incubated with 35S methionine (to a final activity of 0.3 MBq/ml) overnight. They were (1) washed in
Tris-buffered saline and (2) lysed by resuspension in IP buffer (10 mM Tris·HCl, pH
8.0, with 500 mM NaCl, 0.1% Igepal (Sigma, Munich, Germany) and 2 mM phenylmethylsulfonyl
fluoride) and sonication on ice. IP was performed by incubation of patient sera (10
μl) with protein A Sepharose beads (2 mg in 500 μl; Sigma) for two hours, three short
washing steps, end-over-end rotation with the radiolabelled cell extract overnight,
five washing steps, separation of the precipitates on 5% to 20% gradient SDS-PAGE
gels and subsequent autoradiography for six to ten days. Bands typical of autoantibodies
were identified according to their apparent molecular weight and comigration with
bands produced by reference sera with known autoantibody specificity. After we completed
this procedure, the autoantibodies to the following antigens were routinely detectable:
topoisomerase I (Scl-70), RNAPs (I and/or III), Ku, fibrillarin, To, NOR-90, Pl-7,
Pl-12, EJ, OJ, KS, Mi-2, signal recognition particle, ribonucleoprotein (usually U1-RNP),
SL, PCNA, ribosomal P proteins and p25/p23, also known as 'anti-chromo' [30,31]. In our hands, the detection of antibodies to Ro, La, PM-Scl, Jo-1, centromere antigens
and the mitochondrial M2 antigen was unreliable by this method. Bands of unknown nature
were registered and entered into the database of autoantibody results.

Immunodiffusion (ID) was performed in Agarose gels with rabbit and/or calf thymus
extract (Pel-Freez Biologicals, Rogers, AR, USA) as described previously [32]. Autoantibodies were identified by the identity of precipitation lines with patient
sera compared with monospecific prototype sera with known autoantibody specificity.
The use of prototype serum was guided by results of the immunofluorescence pattern
on HEp-2 cells. The following autoantibodies were detectable: topoisomerase 1 (Scl-70),
PM-Scl, Ku, SL, Jo-1, Pl-7, U1-RNP, Sm and La (SS-B). Precipitation bands that did
not merge with any of the prototype sera were registered as unknown autoantibodies
and entered into the database of autoantibody results.

In selected sera, confirmatory assays using recombinant or synthetic antigens (see
Table 1 Antibody detection criteria) were performed. More than one serum sample was available
from 213 patients (from 2 to 25 samples). At least one serum sample per patient was
tested with the whole protocol described in Figure 1, whereas in most cases the follow-up sera drawn were at least partially characterised
with, for example, the HEp-2 cell test. The criteria for classifying sera as positive
for autoantibodies are listed in Table 1 together with additional serological results commonly found and helpful to identify
the antibodies.

In addition to the autoantibodies defined in Table 1 other circulating autoantibodies detected by at least one of the above-mentioned
procedures, either known (for example, anti-histone, anti-dsDNA) or unknown (for example,
either unidentified bands in IP or ID or antinuclear or anticytoplasmic antibodies
on HEp-2 cells without subsequent identification), were registered. Sera which were
negative for ANAs in immunofluorescence on HEp-2 cells but exhibited cytoplasmic fluorescence
in that assay and/or a positive signal in any of the other assays were grouped together
as ANA-negative. Sera without any positive signal, neither defined nor undefined,
in all four assay systems described above were listed as autoantibody-negative.

Statistics

The data were analysed using Microsoft Excel (Microsoft Corp, Redmond, WA, USA) and
SPSS version 14.0 software (SPSS, Inc, Chicago, IL, USA) for tabular and graphic representation.
Statistical evaluation was performed using contingency table tests with the help of
GraphPad Prism version 3.02 software (GraphPad, La Jolla, CA, USA). We calculated
OR and 95% CI data. P-values were calculated using Fisher's exact test. When multiple tests were performed,
P-values below 0.005 were recorded without performing strict Bonferroni correction.
For most variables, less than 5% of data were missing. Quantitative data (erythrocyte
sedimentation rate (ESR), age at disease onset and Rodnan skin score), depending on
the presence or absence of different autoantibodies, were analysed using the Mann-Whitney
rank-sum test.

Results and discussion

Of the 863 SSc patients studied, 513 (59.4%) were classified as having limited disease
and 173 (20.1%) we classified as having diffuse cutaneous disease. Another 108 patients
(12.5%) had a scleroderma overlap syndrome, 64 (7.4%) had undifferentiated connective
tissue disease with scleroderma features and 5 (0.6%) had systemic sclerosis sine
scleroderma.

The frequency of autoantibodies detected in these patients is shown in Table 2. Overall, ANAs were detected in 94.2% of patients. This frequency was similar to
data previously published [12,14,15,33,34] in which ANA frequencies reported were between 85% and 99%. Among our patients with
ANAs, 86.6% (704 of 813) had autoantibodies known to be highly associated with SSc,
and among these latter patients, 96.4% (679 of 704) had antibodies that detected five
antigens: centromere, topoisomerase I, PM-Scl, U1-RNP and RNAPs.

A coincidence of SSc-associated autoantibodies (Table 3) was rare, being detected in only 1.6% patients (11 of 704). The presence of a SSc-associated
antibody without any other autoantibody detectable by the methods used was found at
varying frequencies, being highest for anti-PM-Scl (73.8%) and lower for, for example,
anti-centromere (33.9%) and anti-fibrillarin (33.3%) (see Table 3). That SSc-associated autoantibodies are largely mutually exclusive is well-known
[14,15,35]. Coincidences in individual patients do occur but are rare [33,36,37]. Our study shows that this statement holds true even if all known non-organ-specific,
SSc-associated autoantibodies are sought using a rigorous protocol in all patients.
On the other hand, additional (mainly not SSc-specific) autoantibodies are common
and were detected in about 53% in our patient cohort with SSc-associated antibodies
(and in 55.4% of all of our patients). In 14.0% of patients (n = 121), none of the above-mentioned SSc-associated but other (defined or undefined)
autoantibodies were found, whereas in 4.4% no autoantibodies at all were detected
by the methods used. Defined autoantibodies not regarded as SSc-specific, such as
anti-Ro/La, anti-NOR-90 or AMAs rarely occurred without the evidence of SSc-associated
autoantibodies (Table 3). Antibodies to p25/p23 were detected exclusively in conjunction with ACA.

From 213 patients, more than one serum sample was available (from 2 to 25 samples).
In the majority (86.4%) of cases, the results of follow-up testing remained essentially
the same and differed in ANA titre by up to only two titre steps. In 11.3% (24 patients),
ANA titre changes exceeded two steps (up to eight steps), in two cases ANAs turned
negative, in one case the ANA pattern changed from finely granular to nucleolar and
in only two cases new, additional typical SSc autoantibodies emerged.

The detection of antibodies in different disease subsets is shown in Table 4. It is obvious that ACA and ATA are not exclusive to either the limited or the diffuse
subset. In patients with overlap syndrome, anti-U1-RNP, anti-PM-Scl and anti-synthetase
antibodies are characteristic.

The correlation of demographic features or signs and symptoms of SSc with the presence
or absence of defined autoantibodies was investigated by contingency table analysis.
The frequencies of these features and their positive or negative correlations with
specific autoantibodies are listed in Table 5. For the purpose of clarity, only those comparisons that led to P-values below 0.05 derived by Fisher's exact test are shown. Significance was calculated
without correction of P-values for multiple comparisons, because not all variables used were independent;
however, we are aware of the fact that some of the weak associations listed in Table
5 might have arisen by chance due to the high number of comparisons made. Therefore,
we focused on those differences calculated that were highly significant (P < 0.005; OR printed in bold in Table 5).

Table 5. Correlations of clinical features with SSc associated autoantibodies

Patients with ACA represented 35.9% of all SSc patients and 38.1% of ANA-positive
SSc patients. In accordance with previous reports [8,9,12,15,33,36,38,39], these patients were less often male, were older at disease onset and had a more
limited extension of cutaneous involvement, as documented by a much lower OR for a
Rodnan skin score (RSS) above 10 (Table 5) and by a very significantly lower mean RSS (Table 6). They had less involvement of internal organs (pulmonary fibrosis, cardiac, musculoskeletal
and oral involvement), with the exception of pulmonary hypertension. An association
of ACA with pulmonary hypertension has been observed in several previous reports [2,12,33,40], but not all of them [13,36,38,39]. Digital ulcers in our patients with ACA were less common compared to American patients
[2] and more similar to European [9,12,38] and Japanese patients [34]. Nevertheless, the presence of ACA does not by any means preclude digital ulcers.
To date no marker constellation allows the identification of patients prone to this
complication [41-43]. ACAs are frequently associated with other antibodies, such as anti-Ro [44-46], anti-mitochondrial (M2) [15,44,47,48] and anti-p25/p23 [31,49,50] antibodies. These associations were confirmed by this study. The reasons for this
frequent co-occurrence are unknown. There is no known antigenic relationship between
the individual targets of the antibodies. Probably the (unknown) aetiopathogenetic
pathways marked by these antibodies have common components, including common genetic
predispositions.

Table 6. Correlations of clinical features with systemic sclerosis-associated autoantibodies

The prevalence of ATA in our cohort (30.1%) is in line with the numbers published
by others, which have varied between 13% and 36% [2,8,9,12,14,15,17,33,34,36,51]. The patients with ATA in our study were more likely to be male and had higher RSSs
(Tables 5 and 6). More common in this patient group were digital ulcers, pulmonary fibrosis, dyspnoea,
lung restrictive defect and joint involvement (synovitis, contractures) as well as
mouth involvement. However, renal involvement, as measured by proteinuria or renal
insufficiency, was not more prevalent in this subgroup, a finding reported by most
other researchers [8,9,14,15,33,36,51,52] but not all of them [2,34].

The frequency of RNAP antibodies in our cohort was 3.8%, which is at the lower end
of the frequency range reported by others, namely, 10% to 25% in North America [33,52-55], 4% to 31.5% in Europe [14,16,33,35,56-59] and 5% to 11% in Japan [34,36,60]. This may have several reasons: (1) Our cohort is composed of a broad spectrum of
SSc patients, including patients with milder forms and with overlap or undifferentiated
subtypes of the disease, (2) regional differences due to genetic background and/or
environmental influences and (3) different techniques used to ascertain the presence
of RNAP antibodies. A high mean RSS, reflecting diffuse skin involvement, was evident
for patients with anti-RNAP antibodies (Tables 5 and 6) as previously observed [2,14,33,34,36,40,54-60]. In addition, we found creatine kinase (CK) elevation to be more frequently associated
with the presence of anti-RNAP antibodies. This has not been noted before; association
with muscular involvement has been found to be nonsignificant [14,34,40,53,54] or even inverse [2,36,55] in previous publications. Our result in this study therefore might be a chance finding
due to multiple comparisons. We did not find any significant positive association
of RNAP antibodies, or any autoantibody evaluated in this study, with renal involvement.
In the German Network for Systemic Scleroderma Registry, 'renal involvement' is defined
as renal insufficiency in the form of decreased creatinine clearance and/or proteinuria,
as well as a consequence of acute renal crisis. The registry did not include renal
crisis as a separate item at that time, which may underestimate the possible correlation
of antibodies with renal crisis [18]. Within our network, the frequency of renal crisis currently does not exceed 2% to
3% per year (Hunzelmann N, unpublished observation). The prevalence of renal crisis
among patients with RNAP antibodies reported in the literature (for review, see Meyer
et al. [57]) varies considerably, between 0% and 43%.

Antibodies to fibrillarin (U3-RNP) were most prominent in patients with the diffuse
subtype (table 4), which is in accordance with the findings published in previous reports [2,13,34,40,61]. In fact, patients with anti-fibrillarin antibodies, on average, had the highest
RSS of all patients in our cohort (Tables 5 and 6). The significance of this finding, however, is less pronounced because of the lower
number of patients. The detected anti-fibrillarin antibody frequency of 1.4% was considerably
lower than that reported in previous cohorts (2.5% to 19%) [2,13,34,36,40,61-63], which may reflect our broad spectrum of SSc patients that included patients with
overlap syndrome and undifferentiated forms, as well as methodological differences
and/or the central European background of the patients. Ethnic heterogeneity with
a higher frequency of anti-fibrillarin antibodies in black patients has been described
previously [2,13,40,61-63]. Our findings of a lower age at disease onset and a higher prevalence of musculoskeletal
involvement (Tables 5 and 6) are in line with most previous results [2,36,61,63].

The frequency of PM-Scl antibodies (4.9%) detected in our cohort is in accord with
previously published studies in which frequencies between 2% and 6% were noted for
SSc patients [1-3,17,33]. These antibodies are most well-known as being typical in patients with dermatomyositis-scleroderma
overlap syndrome [1,3]. Accordingly, CK elevation was highly associated with anti-PM-Scl in our cohort.
On the other hand, these patients were markedly less likely to have oesophageal involvement
(Table 5) and had a low mean ESR (Tables 5 and 6). We found elevated ESR levels in an earlier series of SSc patients with anti-PM-Scl
antibodies [32], but others, to the best of our knowledge, did not. (Patients with anti-PM-Scl have
rarely been analysed in the large SSc series reported previously.) Therefore, this
finding has to be reproduced by independent work in the future. That these patients
have a relatively benign prognosis has been mentioned several times before [64-66]. Accordingly, 31% of our patients with anti-PM-Scl antibodies were devoid of any
internal organ involvement, compared with 13% of the patients without anti-PM-Scl
(P = 0.0023, data not shown).

Antibodies to Ku, when found in SSc patients, are often associated with scleroderma
overlap syndrome and with muscular involvement [17,36]. Accordingly, we registered a high OR, but with low significance because of the relatively
low patient number, for CK elevation associated with anti-Ku antibody (Table 5). The complete absence of ACA and the occasional presence of ATA described in a large
previous study that focused on anti-Ku in patients with SSc [17] were nicely reproduced in our cohort (Table 3). Most of our anti-Ku sera (7 of 10) were positive only by IP and negative in a 'classical'
precipitation test with native antigen. In a previous study, on the contrary, a similar
test (counterimmunoelectrophoresis) was even more sensitive than a line assay to anti-Ku.
A possible explanation for this discrepancy might be the source of the antigen, which
was of rabbit origin, in our ID assay. Ku autoantibodies are known to tend to be nonreactive
with nonhuman antigens [67].

Antibodies to p25/p23 ('anti-chromo') characterise a patient subset within the group
of ACA-positive SSc patients. The clinical findings among these patients were heterogeneous
in previous reports. Soriano et al. [49] found an elevated prevalence of erosive arthritis and Furuta et al. [50] reported more interstitial lung disease and liver involvement, whereas Japanese groups
[30,31,68] discovered cytopenias, Sjögren's syndrome, overlap with systemic lupus erythematosus
and higher ESR levels. We confirmed the relatively strong association with Sjögren's
syndrome on the basis of our finding that 20 (71.4%) of 28 patients with p25/p23 antibodies
had sicca symptoms, compared to only 41.7% of SSc patients who were negative for these
autoantibodies (Table 5). In fact, the weak association of ACA with sicca symptoms (OR = 1.44) (Table 5) lost significance when those patients with co-occurring anti-p25/p23 were eliminated.
Likewise, the low mean RSS calculated for ACA-positive patients (6.4) (see Table 6) turned even lower (6.2) after exclusion of patients with anti-p25/p23.

Antibodies to Ro and/or La, as expected and as previously reported [44,45,69,70], were associated with sicca syndrome. This association was only marginally significant;
in fact, the antibodies with the most prominent association with the sicca complex
were, as mentioned above, anti-p25/p23 antibodies. Anti-Ro and/or anti-La antibodies
showed a particularly high correlation with elevated ESR (Tables 5 and 6). An unexpectedly strong association of anti-Ro60 with pulmonary fibrosis (Table
5) was mainly secondary to the relatively high co-occurrence of this antibody with
ATA (see Table 3).

No highly significant differences for any of the autoantibody-defined subgroups could
be found for gastric, intestinal or renal involvement, including hypertension and
reduced renal function. Furthermore, no significant differences dependent on antibodies
against aminoacyl-transfer RNA synthetases, To, Sm, SL or NOR-90 were detected, probably
because of the low numbers of patients positive for these antibodies. Patients without
highly SSc-associated antibodies were more often male and less frequently had Raynaud's
phenomenon.

Conclusions

The occurrence of SSc-related autoantibodies has never been analysed in such detail
in a cohort as large as this one. We have shown that five antigens appear to be sufficient
to detect more than 95% of the known SSc-associated autoantibody responses in ANA-positive
SSc patients. In more than half of patients with a SSc-associated antibody, other
nuclear autoantibodies were detected and a considerable patient group (around 40%)
still displayed uncharacterised ANAs of as yet unknown significance.

To the best of our knowledge, this is the largest comprehensive analysis of the presence
of SSc-associated as well as other non-organ-specific autoantibodies in SSc patients
that was performed in a single central laboratory and demonstrates the complexity
and heterogeneity of the autoimmune response underlying the pathogenesis of this still
enigmatic disease.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

RM designed the study, performed the serological analyses, had full access to all
of the data in the study, analysed the data, takes responsibility for the integrity
of the data and the accuracy of the data analysis, interpreted the data, and drafted
the manuscript. EG designed the study, was responsible for overall project management,
enrolled patients for the network, and contributed data from one participating centre.
TK designed the study and was responsible for overall project management. PM, GR,
MM, FR, MB, MW, NB, RH, AK, CS, AJ, CP, CF, MS, PL, RS, ESL, CS and IF enrolled patients
for the network and contributed the data from the participating centres. IM and UML
were responsible for overall project management, enrolled patients for the network
and contributed the data from the participating centres. NH interpreted the data and
drafted the manuscript, was responsible for overall project management and designed
the study. All authors critically revised the manuscript and read and approved the
final manuscript for publication.

Acknowledgements

The expert technical assistance of Marie-Claire Vondegracht and Rita Bernstein is
gratefully acknowledged. Furthermore, we are indebted to Dr M Blüthner, Laboratory
Prof Seelig, Karlsruhe, Germany, for confirming the anti-To antibodies; to Dr C Will
and Professor R Lührmann, Marburg, Germany, for identification of the anti-U11 RNP
antibodies; and to Dr EK Chan, Gainesville, FL, USA; Prof B Liedvogel, Diarect, Freiburg,
Germany; and Dr W Schlumberger, Euroimmun, Lübeck, Germany, for supplying rabbit anti-sera
to p25/p23, recombinant PM-Scl antigens, and investigational anti-fibrillarin ELISA
kits, respectively. We also thank A Fehr and B Damm for data acquisition and management
and Hildegard Christ and PD Dr Martin Hellmich for statistical advice. This study
was supported by the German Federal Ministry of Education and Research (BMBF) (grants
01GM0310 and 01GM0630).

Khimdas S, Harding S, Bonner A, Zummer B, Baron M, Pope J, Canadian Scleroderma Research Group: Associations with digital ulcers in a large cohort of systemic sclerosis: results
from the Canadian Scleroderma Research Group registry.